Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) Sees Large Increase in Short Interest

Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) saw a significant increase in short interest during the month of October. As of October 15th, there was short interest totaling 195,736 shares, an increase of 191.6% from the September 30th total of 67,129 shares. Currently, 1.2% of the shares of the company are sold short. Based on an average daily trading volume, of 515,895 shares, the short-interest ratio is presently 0.4 days.

Hong Kong Pharma Digital Technology Stock Down 12.3%

Shares of NASDAQ HKPD opened at $1.92 on Friday. Hong Kong Pharma Digital Technology has a fifty-two week low of $1.63 and a fifty-two week high of $29.00. The firm’s 50-day simple moving average is $3.04 and its 200 day simple moving average is $9.38. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.75 and a current ratio of 3.86.

Hong Kong Pharma Digital Technology (NASDAQ:HKPD) last announced its earnings results on Friday, August 7th. The company reported ($0.82) earnings per share (EPS) for the quarter. The company had revenue of $3.15 million for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered Hong Kong Pharma Digital Technology from a “sell (d)” rating to a “sell (e+)” rating in a report on Thursday, August 13th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Hong Kong Pharma Digital Technology Company Profile

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.